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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: There is currently no consensus about the pattern and risk factors of
bladder recurrence after nephroureterectomy, especially in the Chinese population. We eval-
uated the pattern and risk factors based on data from a large Chinese center.
Methods: The clinical and pathological data of 438 patients with upper tract urothelial carci-
noma (UTUC), who underwent nephroureterectomy at Peking University First Hospital, Beijing,
China between 2000 and 2010, was retrospectively analyzed. Univariate analysis by log-rank
test and multivariate analysis by Cox proportional hazards regression model were used to
determine the independent risk factors.
Results: A total of 135 patients (30.8%) developed intravesical recurrence within a median
follow-up of 45 months (range: 12e144 months). The median interval of bladder recurrence
was 15 months (range: 2.0e98.0 months), and the two peaks for recurrence were 4e6 months
and 17e19 months. Lower tumor grade, tumor multifocality, concomitant carcinoma in situ
(CIS) and tumors located in the lower ureter were significant risk factors by univariate and
multivariate analysis. A risk-scoring system was developed and a significant difference was
found between different risk evaluations. Patients with concomitant CIS tended to develop
a late bladder recurrence. One hundred and eighteen patients (87.4%) received transurethral
resection after bladder tumor recurrence.contributing authors have any conflicts of interest, including specific financial interests and re-
the subject matter or materials discussed in the manuscript.
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Bladder recurrence after nephroureterectomy 821Conclusion: Lower tumor grade, tumor multifocality, concomitant CIS and tumors located in
the lower ureter tend to be predictive for bladder recurrence after nephroureterectomy,
although the underlying mechanism is not fully elucidated, and the scoring system could help
risk stratification. Most recurrent tumors could be treated by transurethral resection and there
were two peaks for recurrence, which is probably related to the mechanisms and may be un-
ique to the Chinese population.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Radical nephroureterectomy with excision of the bladder
cuff is the gold standard treatment for localized upper tract
urothelial carcinomas (UTUC).1 The reported recurrence
rate within the bladder after treatment of a primary UTUC
is about 20e50%.2e13 Several studies have attempted to
delineate the clinical and pathological criteria for pre-
dicting such recurrences.2e13 However, most investigations
analyzed a comparatively small number of patients, and to
our knowledge, there are few published reports from
research centers in China. Chinese herbs are mainly
consumed in this cohort of population and have been
proven to be related to urothelial carcinoma,14 and the
incidence of UTUCs in the Chinese population is different
from that of the Western population, although the mech-
anism related to the ethnic difference is still unknown.
Chinese UTUC patients are more likely to be female and
females are less likely to be in a more advanced pathologic
stage than males.15 The recurrence pattern and predictive
factors might be different and experience from Chinese
centers could help understand the recurrence mechanism.
We therefore conducted this study based on data from a
nationwide high volume center in China, in order to identify
these factors in this unique population.
Materials and methods
The follow-up data of patients who were treated at Peking
University First Hospital, Beijing, China for newly diagnosed
UTUC from 2000 to 2010 was reviewed. Among the 631
patients with complete follow-up, 193 were excluded from
the study: 71 had concomitant/previous bladder tumors, 25
had bilateral synchronous UTUCs, 54 underwent other sur-
geries instead of radical nephroureterectomy, 39 had a
follow-up period < 12 months, two had metastasis disease,
and two had a positive surgical margin. The remaining 438
patients were included in this study, and none of these
patients received preoperative chemotherapy, although for
some patients, adjuvant chemotherapy or radiotherapy was
administered when evidence of distant metastasis or
retroperitoneal recurrence was documented.
All patients were diagnosed by computed tomography,
urologic ultrasound, magnetic resonance imaging (MRI), and
in some patients, ureteroscopy with or without biopsy.
Chest X-ray and preoperative cystoscopy were performed in
all patients to rule out metastasis and concomitant bladder
tumor. Urinary cytology specimens included voided speci-
mens, catheterized bladder specimens, and selective
ureteral washings. Surgical approaches included retroperi-
toneal open or laparoscopic nephroureterectomy. Theureter was ligated immediately after the control of the
renal artery without dissecting around the kidney in all
cases (for a tumor located in the lower ureter, the ureter
was ligated in the proximal site of the tumor). Complete
distal ureter and bladder cuff were removed entirely by
extravesical dissection of the distal ureter and the intra-
mural portion within the bladder wall through an open
Gibson incision. Dissection of regional lymph nodes was
performed in patients with suspicious lymph node invasion
on preoperative imaging studies, or those suspected of
having enlarged nodes during intraoperative inspection. All
patients underwent surgery within 2 months after the
occurrence of symptoms.
The follow-up regimen of affected patients included
cystoscopy every 3 months for the first 2 years; cystoscopy
intervals were extended to 1 year thereafter. Chest X-ray,
serum creatine, abdominal ultrasound, and MRI or
computed tomography were examined at the same time.
We defined bladder recurrence as finding a subsequent
bladder tumor during cystoscopy and confirmed it by pa-
thology. The time of first bladder recurrence was used as
the endpoint for the study. The follow-up of patients
without tumor recurrence was censored to the date of their
last visit. In case of death not related to the bladder can-
cer, follow-up was censored to the date of death.
Estimated glomerular filtration rate (eGFR) was calcu-
lated with the modified glomerular filtration rate estimating
equation for Chinese patients.16 Positive cytology was
indicative of malignancy and the presence of atypical cells
that were highly suggestive of urothelial carcinoma. Nega-
tive cytology was defined as no evidence of atypia, atypia
without mention of malignancy, or scant cellular material.
Tumor stage was assessed according to the UICC (Union for
International Cancer Control) TNM classification of malig-
nant tumors 2002. Tumor grading was assessed according to
the World Health Organization (WHO) classification of 1973.
Based on the site of the dominant lesion, tumor location
was defined as renal pelvis or ureter, and ureter was clas-
sified as the upper ureter (above the upper border of the
sacrum), the middle ureter (from the upper to the lower
border of the sacrum), and the lower ureter (below the
lower border of the sacrum).17 Tumor multifocality was
defined as the synchronous presence of two or more path-
ologically confirmed macroscopic tumors in any location.
All statistical tests were performed with SPSS version
20.0 (IBM Corp, Armonk, NY, USA); statistical significance
was set at p < 0.05. Univariate analysis using the log-rank
test and multivariate analysis using Cox’s proportional
hazards regression model were used. The Pearson test and
the Chi-square test were used to test the distribution of
categorical variables. Only variables significant by univari-
ate analysis were considered for the multivariate analysis.
Table 1 Patient demographic and histological data.
Variables N %
Patients 438 100.0
Sex
Male 187 42.7
Female 251 57.3
Age (y)
<70 246 56.2
70 192 43.8
Preoperative renal function
No CKD (eGFR  90) 35 8.0
Early CKD (90 > eGFR  30) 346 79.0
Severe CKD (eGFR < 30) 57 13.0
Urinary cytology
Positive 209 47.7
Negative 104 23.7
Missing data 125 28.5
Surgical approach
Open 292 66.7
Laparoscopic 146 33.3
Presence of hydronephrosis
Presence 228 52.1
Absence 210 47.9
Architecture
Papillary 352 80.4
Sessile 86 19.6
Multifocality
No 356 81.3
Yes 82 18.7
Location
Pelvis 234 53.4
Ureter 204 46.6
Upper ureter 39 8.9
Middle ureter 51 11.6
Lower ureter 114 26.0
Muscle invasion
No 153 34.9
Yes 285 65.1
Tumor stage
Ta 22 5.0
T1 131 29.9
T2 166 37.9
T3 116 26.5
T4 3 0.7
N stage
N0 34 7.7
Nx 394 90.0
Nþ 10 2.3
G grade
G1 15 3.4
G2 264 60.3
G3 159 36.3
Tumor necrosis
No 388 88.6
Yes 50 11.4
Tumor size
3 cm 265 60.5
>3 cm 172 39.3
Table 1 (continued )
Variables N %
CIS
Present 12 2.7
Absent 426 97.3
Adjuvant therapy
Yes 23 5.3
No 415 94.7
CIS Z carcinoma in situ; CKD Z chronic kidney disease;
eGFR Z estimated glomerular filtration rate.
822 D. Fang et al.According to the sum of ln(hazard ratio) of each risk factor
(which is equal to the coefficient in Cox regression), a risk
factor-based stratification model is proposed.2
Results
The demographic information of these patients is summa-
rized in Table 1. The median follow-up time was 45 months
(range: 12e144 months). The median patient age was 66
years (range: 20e88 years). The distribution of UTUC
pathological stage in this cohort was pTa, pT1, pT2, pT3,
and pT4 in 22 (5.0%) patients, 131 (29.9%) patients, 166
(37.9%) patients, 116 (26.5%), and three (0.7%) patients,
respectively. Pathological Grades 1e3 tumors were present
in 15 (3.4%) individuals, 264 (60.3%) individuals, and 159
(36.3%) individuals, respectively. Multiple tumors were
present in 82 patients (18.7%).
Pathology confirmed 135 patients (30.8%) with intra-
vesical recurrence. The median interval of bladder recur-
rence was 15 months (range: 2.0e98.0 months). Ninety-
seven of 135 (71.8%) bladder recurrences were diagnosed
within 2 years after the primary operation. The exact
number of recurrent cases within different months after
surgery are shown in Fig. 1. The two peaks for recurrence
are 4e6 months and 17e19 months.
After first bladder recurrence, 118 (87.4%) patients
received transurethral resection of bladder tumor (14 un-
derwent total cystectomy for multiple recurrence or
bladder tumor progression later during follow-up), seven
patients received total cystectomy, one patient received
partial cystectomy, one patient was treated with radiation
therapy, and therapy modality was unclear for the
remaining eight patients.
In the univariate analysis (Table 2), tumor multifocality
(pZ 0.004), lower tumor grade (pZ 0.010), tumor located
in the lower ureter (pZ 0.005), and concomitant carcinoma
in situ (CIS) (pZ 0.024) were predictive factors for bladder
recurrence (Fig. 2). Rerunning the dataset by comparing
Grades G1 and G2 with Grade G3 did not change the statis-
tical significance of the tumor grade (pZ 0.003). Rerunning
the dataset by comparing a tumor located in the ureter with
a tumor located in the pelvis did not reach a significant
difference (p Z 0.082). Other parameters, including sex,
renal function, and tumor stage, were not related to an
increased risk of intravesical recurrence. In multivariate
analysis (Table 3), tumor multifocality, lower tumor grade,
tumor located in the lower ureter, and concomitant CIS
remained the prognostic factors for recurrence.
Figure 1 Number of bladder recurrence patients in different
time intervals after surgery.
Table 2 Univariate analysis of risk factors for bladder
recurrence.
Variables No. of patients
(no. of recurrences)
p
Sex
Male 187 (62) 0.235
Female 251(73)
Age (y)
<70 246 (83) 0.255
70 192 (52)
Preoperative renal function
No CKD (eGFR  90) 35 (10) 0.897
Early CKD (90 > eGFR  30) 346 (107)
Severe CKD (eGFR < 30) 57 (18)
Urinary cytology
Positive 209 (70) 0.636
Negative 104 (30)
Missing data 125 (35)
Surgical approach
Open 292 (87) 0.279
Laparoscopic 146 (48)
Presence of hydronephrosis
Presence 228 (72) 0.388
Absence 210 (63)
Architecture
Papillary 352 (112) 0.692
Sessile 86 (23)
Multifocality
No 356 (98) 0.004*
Yes 82 (37)
Tumor located in lower ureter
Yes 114 (45) 0.005*
No 324 (90)
Muscle invasion
No 153 (49) 0.744
Yes 285 (86)
Tumor stage
Ta 22 (8) 0.684
T1 131 (41)
T2 166 (55)
T3 116 (31)
T4 3 (0)
N stage
N0 34 (12) 0.127
Nx 394 (123)
Nþ 10 (0)
G grade
G1 15 (8) 0.010*
G2 264 (92)
G3 159 (35)
Tumor necrosis
No 388 (117) 0.213
Yes 50 (18)
Tumor size
Bladder recurrence after nephroureterectomy 823To construct the risk stratification model with consid-
eration of all coefficients, we defined each score as the
approximate value of 2  ln(hazard ratio of each
factor) þ constant. Finally, the constant value was defined
as two, to help calculations, and each risk factor was
scored as follows: tumor Grade 1 Z two points, tumor
Grade 2 Z one point, tumor Grade 3 Z zero points; mul-
tiple tumors Z three points, single tumor Z two points;
presence of CISZ four points, absence of CISZ two points;
tumor located in the lower ureter Z three points, and in
other positionsZ two points. All 438 patients were divided
into four risk groups (low, low-intermediate, high-inter-
mediate, or high) according to the sum of their risk factors
score (6, 7, 8, and 9 or more, respectively). There was a
significant difference in bladder recurrence-free survival
between the three risk groups with p < 0.001 (Fig. 3).
When the risk factors for early recurrence and late
recurrence were compared (we set the cut-off as 15 months
according to the median recurrence interval, by which the
two peaks were located in different groups), the only dif-
ference was the proportion of cases with concomitant CIS
(Table 4).
There were 71 deaths (16.2%) altogether during follow-
up (including 46 cancer specific deaths), and bladder
recurrence developed in 23 of this cohort of patients. If we
exclude those patients who died during follow-up without
bladder recurrence, multifocality, and tumor located in the
lower ureter remained risk factors (p Z 0.007 and
p Z 0.004, respectively). Lower tumor grade and
concomitant CIS were nearly significant (p Z 0.061 and
p Z 0.054, respectively). By log-rank test, no differences
were found between patients with or without bladder
recurrence in terms of cancer specific survival (pZ 0.796),
or overall survival (p Z 0.897). 3 cm 265 (85) 0.569
>3 cm 172 (49)
CIS
Present 12 (8) 0.024*
Absent 426 (127)
(continued on next page)Discussion
Recurrent bladder tumors after nephroureterectomy
require transurethral resection, which is associated with
Table 2 (continued)
Variables
No. of patients
(no. of recurrences) p
Adjuvant therapy
Yes 23 (7) 0.981
No 415 (128)
*Statistically significant.
CIS Z carcinoma in situ; CKD Z chronic kidney disease;
eGFR Z estimated glomerular filtration rate.
824 D. Fang et al.surgery complications, higher costs of treatment, and po-
tential further radical cystectomy. Because the prophy-
lactic ability of intravesical chemotherapy in preventing
bladder recurrence after nephroureterectomy is being
advocated,18 the precise understanding of recurrence
pattern and the accurate prediction of bladder tumors can
assist clinicians in clinical risk stratification, adjuvant
therapy option, and surveillance arrangement.Figure 2 KaplaneMeier estimated intravesical recurrence (IV
(pZ 0.004); (B) lower tumor grade (pZ 0.010); (C) tumor located
situ (CIS) (p Z 0.024).Several studies have attempted to delineate clinico-
pathological criteria for predicting intravesical
recurrence.2e13 Most of them covered <300 cases, and
cases with conservative surgery modality or follow-up of
<12 months were included in some articles. We evaluated
most of the previously published predictive variables. His-
tory of bladder tumor was believed to be relevant to
bladder recurrence after nephroureterectomy in some
studies,8,12 but we think that it is proper to exclude those
with a prior history of bladder cancer and/or those with
concomitant bladder cancer from this series, as bladder
tumor growth might represent recurrent local disease un-
related to upper urinary tract carcinoma.
Multifocality is proven to be related to intravesical
recurrence in several investigations2,3,9,12 and is currently
the most reliable risk factor for predicting bladder tumor
recurrence. Synchronous/metachronous bladder cancer
could be attributed as an aspect of multifocal urothelial
cancer.
Ureteral involvement of the primary tumor is also a
significant risk factor in previous reports.5,6,13 ZigeunerR)-free survival curves stratified by (A) tumor multifocality
in lower ureter (pZ 0.005); and (D) concomitant carcinoma in
Table 3 Multivariate analysis of risk factors for bladder
recurrence.
Variable Coefficient Hazard
ratio
95% CI p
Grade 0.544 0.580 0.421e0.799 0.001*
Multifocality 0.461 1.586 1.085e2.319 0.017*
CIS 0.956 2.601 1.232e5.490 0.012*
Lower ureter 0.468 1.596 1.108e2.300 0.012*
*Statistically significant.
CI Z confidence interval; CIS Z carcinoma in situ.
Table 4 Comparison between early and late recurrence.
Early
recurrence
Late
recurrence
Chi-square
test
p
Grade 2.293 0.318
G1 2 6
G2 47 45
G3 19 16
Multifocality 0.399 0.331
No 51 47
Yes 17 20
CIS 8.631 0.003*
Present 0 8
Absent 68 59
Lower ureter 0.237 0.716
Yes 24 21
No 44 46
*Statistically significant.
CIS Z carcinoma in situ.
Bladder recurrence after nephroureterectomy 825et al5 concluded that the higher urine flow rate and intra-
luminal pressure in the ureter lead to increased mechanical
irritation and possible subsequent detachment of tumor
cells. Tumors in the pelvis tend to have a better bladder
recurrence-free survival in our study (p Z 0.082) but sta-
tistical differences only exist between tumors in the lower
ureter and other lesions. Two previous papers showed a
positive correlation between lower ureteral lesions and
bladder recurrence.4,6 The early ligation in the distal site of
tumors located in other lesions might play an important role
in preventing tumor implantation.
Two studies have reported the association of concomi-
tant CIS with bladder recurrence.7,12 Pieras et al7 thought
that the presence of CIS indicated that, besides the primary
tumor, there might be changes in the mucosa adjacent to
and further from the initial tumor, which could be the
origin of the appearance of new tumors; it reflects a pre-
malignant state of the entire urinary bladder surface.
However, the prevalence of concomitant CIS varied in
different studies on UTUC,7,12,19 and the number of pa-
tients with CIS in our study is limited, which hampered the
significance.Figure 3 KaplaneMeier estimated intravesical recurrence
(IVR)-free survival curves stratified by risk group (p < 0.001).It is relatively difficult to explain the negative implica-
tions of a lower tumor grade for bladder cancer recurrence.
Because tumor grade is strictly related to cancer aggres-
siveness and tumor stage, it represents a well-established
predictor of cancer-related survival,20 but there is no
consensus on the possible influence of tumor grade on
subsequent bladder cancer recurrence. Bloom et al21
agreed with our study that lower tumor grade related to
bladder recurrence, whereas Zigeuner et al5 and Huang
et al10 found a correlation between higher tumor grade and
intravesical recurrence. It is notable that tumor stage had
no negative role for bladder recurrence in our research and
the conclusions are also controversial in previous trials;
lower tumor stage2,3,21 as well as higher tumor stage7,9,13
was proved to be related to intravesical recurrence in
different studies.
In our research, we consider two potential reasons
behind the predictive role of lower grade on bladder
recurrence. On the one hand, higher tumor grade is related
to more cancer-specific deaths. Patients may die from
tumor dissemination before bladder tumor development is
detectable.5 After excluding those patients who died during
follow-up without bladder recurrence, the influence of
tumor grade on bladder recurrence was not that significant,
with pZ 0.061. On the other hand, a higher tumor grade is
related to cancer aggressiveness and distant metastasis,
but the mechanism for bladder recurrence might be
different. Hisataki et al9 proposed that patients with a high
risk of intravesical recurrence do not necessarily have a risk
of progression to muscle invasion. Besides, the determina-
tion of tumor grade according to WHO 1973 (not the clas-
sification of WHO/International Society of Urologic
Pathology) might also contribute to this result.
The field cancerization hypothesis22 and intraluminal
seeding23 are currently the two main concepts to explain
the multifocality of urothelial cancer and the recurrent
bladder tumor, and the two mechanisms could co-exist.24
Independent multiclonal tumor development after carcin-
ogen exposure of the entire urothelial and intraluminal
826 D. Fang et al.implantation, followed by single progenitor cell induced
clonally evolution are the mechanisms suggested. We
consider that there might be a possible correlation between
lower grade and the molecular recurrent mechanism;
carcinogen exposure to an entire urothelial layer might
easily induce carcinoma with low tumor grade, or a weakly
aggressive low grade tumor cell might easily drop from the
urothelial layer to cause intraluminal seeding. However,
biochemical study is required to further clarify these
propositions.
The median interval of bladder recurrence was 15
months, and >70% recurrence occurred 2 years after
nephroureterectomy. However, with surveillance, the lat-
est intravesical recurrence was found 98 months after
surgery, which means that the period of high risk for
recurrence is about 2 years after nephroureterectomy;
after this, the hazard continued over a long period of time
as previously reported.11 The two peaks for recurrence
have never been reported, and they might be correlated to
the mechanisms for recurrence.
Regarding intravesical recurrence after primary bladder
cancer, Hinotsu et al25 proposed that the early recurrence
be considered the “true recurrence”, and the late recur-
rence be explained as “new second recurrence”. Takaoka
et al11 also proposed the “two phase” regarding intravesical
recurrence after UTUC, and that the early recurrent
pattern might reflect the seeding hypothesis, whereas the
late one reflects the field cancerization hypothesis. By
comparison of early and late recurrence in our study, pa-
tients with CIS tended to develop a late recurrence, and
because the presence of CIS reflects a premalignant state
of the entire urinary surface,7 independent multiclonal
tumor development (the field cancerization hypothesis)
might play a dominant role in this cohort of patients. In
addition, considering Chinese herbs are mainly consumed in
this cohort of population and aristolochic acid might bring
nephrotoxic and carcinogenic toxins to induce neoplasm of
the whole urothelial field,26,27 the recurrence mechanisms
might be unique. This assumption of a relationship between
the recurrence pattern and mechanism requires molecular
genetic studies, and the discovery of a mechanism for
recurrence would help to explain the clinicopathological
factors for recurrence; also, molecular and histological
markers could be useful in daily practice in the future.28
Because most cancers that subsequently developed in
the bladder could be managed by transurethral resection,
and survival analysis indicates recurrent bladder tumor is
not a poor prognostic factor, the surveillance and treat-
ment of recurrent bladder tumor could be individualized.
Limitations of this study include the retrospective design
and data collection, thus subject to selection and recall
bias. The proportion of patients with G1 and concomitant
CIS is too small, and only a few patients underwent lymph
node dissection. The incidence of UTUCs in the Chinese
population is much higher than that of the Western popu-
lation and the biology may be different, and although the
mechanism related to these ethnic differences is still not
fully known, dietary exposure to toxins may play a major
role.29 Despite these limitations, our research is currently
the largest single-center study on intravesical recurrence
after nephroureterectomy in the Chinese population. Pro-
spective investigations combining molecular genetic studiesare required to help realize the exact mechanism for
bladder recurrence and improve the predictive
performance.
In conclusion, lower tumor grade, tumor multifocality,
concomitant CIS, and tumors located in the lower ureter
tend to be predictive for bladder recurrence after neph-
roureterectomy, although the underlying mechanism is not
fully elucidated. The risk-stratification model may help
clinicians in postoperative follow-up and adjuvant therapy.
Most recurrent tumors could be treated by transurethral
resection and there are two peaks for recurrence, which is
probably related to the mechanisms of bladder cancer
recurrence and may be unique for the Chinese population.References
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